• complete remission rate [ Time Frame: at the time point 3 months after CAR-T cell transfusion ]
  complete remission rate after treated by CAR-T therapy
• adverse events [ Time Frame: from the date of the start of treatment to 24 months after last patient's enrollment ]
  any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure

• progression free surviva [ Time Frame: from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment ]
  from date of inclusion to date of progression, relapse, or death from any cause
• overall survival [ Time Frame: from the day of treatment to the date of first documented progression，up to 24 months after the last patient's enrollment ]
  from the date of inclusion to date of death, irrespective of cause
• duration of the CAR-T cells in the patients [ Time Frame: from the date of re-transfusison to 24 months after last patient's enrollment ]
  time from re-transfusion to date when the modified T cells become non-detectable.

Inclusion Criteria:

• 1. Age 18-75 years old, male or female;
• 2. ECOG 0-3, for patients with ECOG=4, if ECOG reach 0-3 after bridging treatment with ibrutinib, they are also considered to fit this criteria;
• 3. Histologically diagnosed as B cell non-Hodgkin's lymphoma (NHL)(according to WHO 2008 criteria), including DLBCL-NOS, primary mediastinal B cell lymphoma (PMBCL) mantel cell lymphoma (MCL), transformed follicular lymphoma (TFL) and other transformed B cell NHL;
• 4. CD19 positive (by immuno-histology or flowcytometry) [for DLBCL/PMBCL/TFL patients, negative CD19 immuno-histology results also acceptable];

• 5. Definition of relapsed and refractory disease: 1) refractory DLBCL should fit one of the following: ①complete remission NOT achieved after 2nd line treatment; ②progression of disease during treatment; ③duration of stable disease <6 months; ④ disease progress or relapse within 12 months of autologous stem cell transplantation.

  2) definition of refractory/relapsed disease for CLL and other indolent B cell NHL, should fit one of the following: ① failed or relapsed after 2nd therapy (Rituximab must be included) and being unable to accept ibrutinib treatment due to various reasons; ② non-responsive or intolerable to ibrutinib as 2nd line treatment; 3) refractory or relapsed MCL should fit one of the following: ① complete remission not achieved after 2nd line treatment; ② disease progression during treatment; ③duration of stable disease ≤6 months; ④disease progress or relapse within 12 months of autologous stem cell transplantation.

• 6. Previous treatment of aggressive B lymphomas must include Rituximab and anthracyclines;
• 7. Patients should have at least one measurable disease focus, with the longitudinal diameter ≥1.5cm, or any extra-nodal focus with the longitudinal diameter ≥1.0cm, with PET/CT positive results;
• 8. Blood routine test, absolute neutrophil count≥1000/ul、platelet count≥45000/ul；
• 9. Cardiac, hepatic and renal function: Creatinin <1.5 times of normal maximum；ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of ULN；cardiac ejection fraction≥ 50%;
• 10. Patients should have the ability to fully understand contents of the written consent and be willing to sign the written consent;
• 11. Fertile patients should agree to take contraceptive measures during the process of this trial.

Exclusion Criteria:

• 1. History of other malignant tumor;
• 2. History of autologous stem cell transplantation within 6 weeks prior to enrollment;
• 3. Received CAR-T therapy within 3 months prior to enrollment;
• 4. Received cytotoxic medicine or glucocorticoids or other targeted-therapy medicine (except for ibrutinib) within 2 weeks prior to T cell collection;
• 5. With active autoimmune disease;
• 6. With active infection;
• 7. With HIV infection, or uncontrolled HBV/HCV/syphilis infection;
• 8. With known central nervous system lymphoma.